Index News Seller Buyer Product Company

Orlistat CAS:*-58-2

  • Date Listed:2018-05-25 09:13:43
    Country:China>Jiangsu>Suzhou
    Jinfeng international community, Jinfeng Road, High-tech Zone
    Company:JIANGSU WATSON BIOTECHNOLOGY CO.,LTD
    Mobile:15072758944
    Tell15072758944

    Orlistat CAS:*-58-2 Hello,dear friend,don't hesitate to contact us,we are sure to be your best supplier! Skype:live:sale8_120 Email:*ology.com Twitter:Lill*nSale8 Product Description Wholesale Price of Orlistat Powder Dosage and Effect CAS:*-58-2 Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet. Orlistat Basic Info. Product Name: Orlistat CAS: *-58-2 MF: C29H53NO5 MW: 495.73 Appearance: White Powder Chemical Properties: mp: <50 °C storage temp: 2-8°C solubility DMSO: 19 mg/mL appearance: Off-White Solid Orlistat Usage: 1. An antiobesity agent. A pancreatic lipase inhibitor. Antiobesity agent. 2. antidiabetic 3. Orlistat is an antiobesity agent. Orlistat is an pancreatic lipase inhibitor. 4. Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity. 5. Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat. After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost. 6. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Long-

    Avoid fraud by meeting all sellers in-person to pay for items. BestB2B.COM does not offer any transaction or payment services.

PC | Touch

About | Contact | BBS | @2024 bestb2b.com

©BestB2B